{"id":"https://openalex.org/W4282974024","doi":"https://doi.org/10.1158/1538-7445.am2022-3431","title":"Abstract 3431: Dose range finding study in non-human primates confirms the unique mechanism of action of CTX-8371, a novel bispecific antibody blocking PD-1 and PD-L1","display_name":"Abstract 3431: Dose range finding study in non-human primates confirms the unique mechanism of action of CTX-8371, a novel bispecific antibody blocking PD-1 and PD-L1","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282974024","doi":"https://doi.org/10.1158/1538-7445.am2022-3431"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-3431","doi":"https://doi.org/10.1158/1538-7445.am2022-3431","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-3431","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065592547","display_name":"Diana I. Albu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana I. Albu","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013803583","display_name":"Xianzhe Wang","orcid":"https://orcid.org/0000-0002-6237-9461","observed_orcids":["https://orcid.org/0000-0002-6237-9461"]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xianzhe Wang","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103959025","display_name":"Yan Qin","orcid":"https://orcid.org/0009-0004-3100-3308","observed_orcids":["https://orcid.org/0009-0004-3100-3308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Qin","raw_affiliation_strings":["2Fuhong Therapeutics, Lexington, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fuhong Therapeutics, Lexington, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101536026","display_name":"Vivian Li","orcid":"https://orcid.org/0000-0003-2971-2610","observed_orcids":["https://orcid.org/0000-0003-2971-2610"]},"institutions":[{"id":"https://openalex.org/I1925986","display_name":"Loyola University Chicago","ror":"https://ror.org/04b6x2g63","country_code":"US","type":"education","lineage":["https://openalex.org/I1925986"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivian Li","raw_affiliation_strings":["3Stritch School of Medicine, Loyola University, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Stritch School of Medicine, Loyola University, Chicago, IL;","institution_ids":["https://openalex.org/I1925986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051370438","display_name":"Purushothama Nanjappa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Purushothama Nanjappa","raw_affiliation_strings":["4Bristol Myers Squibb, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Bristol Myers Squibb, Cambridge, MA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090574939","display_name":"Amy Daniel Ulumben","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Daniel Ulumben","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012153927","display_name":"Ruturaj Jadhav","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruturaj Jadhav","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jason Kong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Kong","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035871469","display_name":"Austin Ablicki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Austin Ablicki","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055329103","display_name":"Neal S. Schilling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal Schilling","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas Schuetz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Schuetz","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029086303","display_name":"Susan L. Kalled","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Kalled","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Bing Gong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bing Gong","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039408547","display_name":"Nelly A. Kuklin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405273323","display_name":"Compass Therapeutics, Inc. (United States)","ror":"https://ror.org/05nhdv432","country_code":"US","type":"company","lineage":["https://openalex.org/I4405273323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nelly Kuklin","raw_affiliation_strings":["1Compass Therapeutics INC, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Compass Therapeutics INC, Boston, MA;","institution_ids":["https://openalex.org/I4405273323"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"3431","last_page":"3431"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9160000085830688},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8339999914169312},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":1.0},{"id":"https://openalex.org/keywords/mechanism-of-action","display_name":"mechanism of action","score":0.8029999732971191},{"id":"https://openalex.org/keywords/dose-range-finding","display_name":"dose range finding","score":0.8550000190734863},{"id":"https://openalex.org/keywords/cynomolgus-macaques","display_name":"cynomolgus macaques","score":0.8930000066757202},{"id":"https://openalex.org/keywords/receptor-occupancy","display_name":"receptor occupancy","score":0.6959999799728394},{"id":"https://openalex.org/keywords/pharmacokinetics-pharmacodynamics","display_name":"pharmacokinetics/pharmacodynamics","score":0.8009999990463257},{"id":"https://openalex.org/keywords/t-cell-depletion","display_name":"T cell depletion","score":0.5329999923706055},{"id":"https://openalex.org/keywords/tumor-bearing-mice","display_name":"tumor-bearing mice","score":0.574999988079071},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.5099999904632568},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.4180000126361847},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.3100000023841858}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7393466830253601},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6354239583015442},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.5599277019500732},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.5543349981307983},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5379027128219604},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5315648913383484},{"id":"https://openalex.org/C196166836","wikidata":"https://www.wikidata.org/wiki/Q902926","display_name":"Immunophenotyping","level":3,"score":0.516040563583374},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.49880409240722656},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.49100688099861145},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.43918704986572266},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.4366396367549896},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43569236993789673},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.41468125581741333},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3567134141921997},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33386942744255066},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2694423794746399},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21638581156730652},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21101024746894836},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1654496192932129},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0830872654914856},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-3431","doi":"https://doi.org/10.1158/1538-7445.am2022-3431","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-3431","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3171340084","https://openalex.org/W7162534401","https://openalex.org/W4391882915","https://openalex.org/W4409822135","https://openalex.org/W4388048300","https://openalex.org/W4220710445","https://openalex.org/W3029868931","https://openalex.org/W2954313239","https://openalex.org/W4282972041","https://openalex.org/W3212518782"],"abstract_inverted_index":{"Abstract":[0],"Multiple":[1],"antibodies":[2],"blocking":[3,498],"PD-1":[4,67,77,170,237,402,411,416,499],"or":[5,131,136,155],"PD-L1":[6,501],"have":[7],"been":[8],"approved":[9],"for":[10,24,139,278,444,509],"clinical":[11],"use.":[12],"However,":[13],"not":[14],"all":[15,233],"patients":[16],"successfully":[17],"respond":[18],"to":[19,118,186,264,314,423],"monotherapy":[20],"and":[21,45,104,164,171,192,207,221,230,248,258,268,350,360,387,412,434,500],"the":[22,55,105,152,159,240,275,301,367,395,404,487,506],"need":[23],"combinations":[25],"has":[26],"become":[27],"more":[28],"apparent.":[29],"CTX-8371":[30,39,62,80,109,115,212,261,290,370],"combines":[31],"PD-1/PD-L1":[32,42],"targeting":[33],"in":[34,43,46,73,89,99,110,123,199,215,225,246,249,283,295,305,355,374,483],"one":[35],"bispecific,":[36],"tetravalent":[37],"molecule.":[38],"potently":[40],"blocks":[41],"vitro":[44,100,375],"vivo.":[47],"This":[48],"robust":[49],"activity":[50],"may":[51,418],"be":[52,265,315],"explained":[53],"by":[54,79,177],"unique":[56,396,488],"mechanism":[57,489],"of":[58,61,76,93,108,142,219,260,307,327,353,383,398,401,410,490,492,505],"action":[59,491],"(MOA)":[60],"which":[63,272,303,323],"involves":[64],"cell":[65,241,405],"surface":[66],"cleavage.":[68],"Here":[69],"we":[70],"present":[71],"further":[72],"vivo":[74,250],"evidence":[75],"cleavage":[78,238,400],"detected":[81],"during":[82],"a":[83,124,140,216,279,440,494],"dose":[84,161,234,302,363,443],"range":[85,480],"finding":[86,481],"(DRF)":[87],"study":[88,95,482],"cynomolgus":[90,120,296,385],"macaques.":[91],"Results":[92],"this":[94],"as":[96,98,430,432],"well":[97,293,431],"receptor":[101],"occupancy":[102],"(RO)":[103],"PK/PD":[106,436],"profile":[107],"tumor-bearing":[111,200,299],"mice":[112,201,354],"are":[113],"described.":[114],"was":[116,173,184,196,292,312,340,343],"administered":[117],"female":[119],"monkeys":[121],"(n=3/group)":[122],"single":[125],"intravenous":[126],"infusion":[127,291],"at":[128,134,232,322,324],"2":[129,143,229],"mg/kg":[130,166,359,362],"weekly":[132],"infusions":[133],"10":[135,163,361],"50":[137,165],"mg/kg,":[138,357],"total":[141],"doses.":[144],"PBMCs":[145,176,226],"were":[146,262],"isolated":[147],"before,":[148],"24":[149,156],"hours":[150,157],"after":[151,158],"first":[153],"dose,":[154,321],"second":[160],"(for":[162],"groups).":[167],"Immunophenotyping,":[168],"including":[169],"PD-L1,":[172,413],"performed":[174],"on":[175,227,377],"flow":[178],"cytometry.":[179],"Mean":[180],"serum":[181],"concentration-time":[182],"data":[183,252,429],"analyzed":[185],"derive":[187],"PK":[188,195],"parameters":[189],"using":[190,202],"noncompartmental":[191],"two-compartment":[193],"models.":[194],"also":[197,371],"determined":[198],"an":[203],"MSD":[204],"ELISA-based":[205],"assay":[206],"non-compartmental":[208],"analysis.":[209],"In":[210,298],"monkeys,":[211],"administration":[213],"resulted":[214],"marked":[217],"decrease":[218],"PD-1+CD4+":[220],"PD-1+CD8+":[222],"T":[223,378],"cells":[224,379],"days":[228],"9":[231],"levels,":[235],"indicating":[236],"from":[239,254,380,403],"surface.":[242,406],"These":[243],"results":[244,304],"confirm":[245,394],"vitro,":[247],"MOA":[251,397],"obtained":[253],"mouse":[255],"studies.":[256],"Clearance":[257],"half-life":[259],"calculated":[263],"~6.87":[266],"mL/day/kg":[267],"5.45":[269],"days,":[270,339],"respectively,":[271,365],"fall":[273],"within":[274],"expected":[276],"ranges":[277],"human":[280,442],"IgG1":[281],"antibody":[282,497],"non-human":[284,484],"primates":[285,485],"(NHP)":[286],"with":[287,415],"linear":[288],"PK.":[289],"tolerated":[294],"monkeys.":[297],"mice,":[300],"50%":[306,326,332],"maximum":[308],"tumor":[309,333],"growth":[310,334],"inhibition":[311,335],"found":[313],"1-2":[316],"mg/kg.":[317],"The":[318,407],"minimum":[319],"effective":[320],"least":[325],"animals":[328],"exhibit":[329],"greater":[330],"than":[331],"over":[336],"two":[337],"consecutive":[338],"1mg/kg.":[341],"It":[342],"observed":[344],"that":[345],"11%":[346],"(1/9),":[347],"78%":[348],"(7/9)":[349],"100%":[351],"(9/9)":[352],"0.1":[356],"1":[358],"groups,":[364],"meet":[366],"above":[368],"criteria.":[369],"showed":[372],"dose-dependent":[373],"RO":[376,428],"peripheral":[381],"blood":[382],"human,":[384],"monkey,":[386],"transgenic":[388],"hPD-1hPD-L1":[389],"mice.":[390],"Data":[391],"presented":[392],"here":[393],"CTX-8371,":[399,493],"dual":[408],"blockade":[409],"combined":[414],"cleavage,":[417],"offer":[419],"superior":[420],"benefit":[421],"compared":[422],"current":[424],"checkpoint":[425],"inhibitor":[426],"therapies.":[427],"murine":[433],"NHP":[435],"analyses":[437],"will":[438],"guide":[439],"projected":[441],"future":[445],"development.":[446],"Citation":[447],"Format:":[448],"Diana":[449],"I.":[450],"Albu,":[451],"Xianzhe":[452],"Wang,":[453],"Yan":[454],"Qin,":[455],"Vivian":[456],"Li,":[457],"Purushothama":[458],"Nanjappa,":[459],"Amy":[460],"Daniel":[461],"Ulumben,":[462],"Ruturaj":[463],"Jadhav,":[464],"Jason":[465],"Kong,":[466],"Austin":[467],"Ablicki,":[468],"Neal":[469],"Schilling,":[470],"Thomas":[471],"Schuetz,":[472],"Susan":[473],"Kalled,":[474],"Bing":[475],"Gong,":[476],"Nelly":[477],"Kuklin.":[478],"Dose":[479],"confirms":[486],"novel":[495],"bispecific":[496],"[abstract].":[502],"In:":[503],"Proceedings":[504],"American":[507],"Association":[508],"Cancer":[510,521],"Research":[511],"Annual":[512],"Meeting":[513],"2022;":[514],"2022":[515],"Apr":[516],"8-13.":[517],"Philadelphia":[518],"(PA):":[519],"AACR;":[520],"Res":[522],"2022;82(12_Suppl):Abstract":[523],"nr":[524],"3431.":[525]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-06-17T00:00:00"}